Enzene Biosciences has announced the formation of a new drug discovery branch. This broadens the CDMO's service offerings to the biotech industry and complements its EnzeneXTM-equipped biologics manufacturing location in the United States, which will launch later this summer.
In response to rapidly increasing industry demands, the CDMO is launching its new discovery arm, which will deliver end-to-end integrated discovery services. The discovery options will comprise antibody services (target validation, discovery, and engineering), reagent manufacture (ranging from bespoke peptides and proteins to advanced modalities like as plasmids, RNA, and exosomes), and multi-platform assay services. While financial details are unknown, the new Discovery Division will be based in the company's Pune site, with new cutting-edge discovery facilities expected to be operational by July and other expansions planned later in the year.
“There is a global shortage of biology services, and our clients are increasingly looking to collaborate with us much earlier in the discovery phase to expedite their progress to IND and beyond. We anticipate even greater demand for these services in the coming year as the resurgence in biotech funding leads to more targets entering discovery – with contract R&D empowering them to advance more targets simultaneously. For our big pharma partners, in addition to running the integrated programmes, we provide the flexibility to easily outsource non-core activities. In particular, we have seen strong demand for high-quality reagents and assay services that play a crucial role across drug discovery and development, commented Dr Himanshu Gadgil, CEO, Enzene Biosciences.
, CDSCO.jpg)
.jpg)